LOGIN  |  REGISTER
Astria Therapeutics
Amneal Pharmaceuticals

Alignment Healthcare to Announce Third Quarter 2023 Financial Results and Host Conference Call Thursday, Nov. 2, 2023

October 12, 2023 | Last Trade: US$18.24 1.24 -6.37

ORANGE, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), will release its third quarter 2023 financial results on Thursday, Nov. 2, after market close. Following the release, the company will host a conference call to review its financial results at 5:30 p.m. EDT.

Conference Call Details

A live audio webcast will be available online at https://ir.alignmenthealth.com/. At the start of the conference call, participants may access the webcast by clicking here.

A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call at the same web links and will remain available for approximately 12 months.

About Alignment Health

Alignment Health is championing a new path in senior care that empowers members to age well and live their most vibrant lives. A consumer brand name of Alignment Healthcare (NASDAQ: ALHC), Alignment Health is a tech-enabled Medicare Advantage company that offers more than 40 benefits-rich, value-driven plans that serve 52 counties across six states. The company partners with nationally recognized and trusted local providers to deliver coordinated care, powered by its customized care model, 24/7 concierge care team and purpose-built technology, AVA®. Based in California, the company’s mission-focused team makes high-quality, low-cost care a reality for members every day. As it expands its offerings and grows its national footprint, Alignment upholds its core values of leading with a serving heart and putting the senior first. For more information, visit www.alignmenthealth.com.

Investor Contact
Harrison Zhuo
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact
Maggie Habib
mPR, Inc. for Alignment Health
This email address is being protected from spambots. You need JavaScript enabled to view it.

Astria Therapeutics

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page